FDA Approves KEYTRUDA® (Pembrolizumab) for Perioperative Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Merck known as MSD outside the United States and Canada, recently announced that…
Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Clinical Results in Large B-Cell Lymphoma Johnson & Johnson recently presented promising first-in-human data from its ongoing Phase 1b study…
Dapirolizumab Pegol Shows Disease Activity Reduction and Fatigue Improvement in SLE at EULAR 2025 UCB and Biogen today presented additional and detailed results from the Phase 3 PHOENYCS GO study…
Merck Highlights Positive Enpatoran Phase 2 WILLOW Study Data in SLE at EULAR 2025 Merck, a leading science and technology company, today presented new and detailed results from its Phase…
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of…
Bristol Myers Squibb Highlights Targeted Protein Degradation Advances, Including CELMoD Agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy Bristol Myers Squibb today revealed new and updated data…
EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and…
Novartis’ Fabhalta Shows Meaningful Hemoglobin Improvement in PNH Patients, Reinforcing Benefit of Oral Monotherapy Novartis recently announced positive results from its APPULSE-PNH study — a Phase IIIB trial evaluating Fabhalta®…
Merck Animal Health Wins Positive EU CVMP Opinion for NUMELVI (atinvicitinib) Tablets for Dogs Merck Animal Health, a division of Merck & Co known as MSD Animal Health outside the…
Bleximenib Shows Promise in AML When Combined with Venetoclax and Azacitidine, According to Johnson & Johnson’s Phase 1b Data Presented at EHA 2025 Johnson & Johnson today presented new and…
Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced the dosing of the first…
Global Parliamentarians Take the Stage at WHA78: A New Chapter in Health Governance The Seventy-eighth World Health Assembly (WHA78), held in Geneva in 2025, emerged as a landmark moment in…
